[
  {
    "ts": "2026-02-04T03:18:28+00:00",
    "headline": "Merck Deepens Oncology And Vaccine Bets With Partnerships And Equity Stake",
    "summary": "Merck (NYSE:MRK) has taken a significant equity stake in Eikon Therapeutics, expanding its presence in oncology-focused biotech. The company has entered a global oncology collaboration with Guardant Health to advance cancer diagnostics and treatment approaches. Merck is also leading efforts to improve global access to vaccines targeting Zaire ebolavirus, aiming to broaden distribution and use. For you as an investor, these moves sit squarely within Merck's core areas in cancer and vaccines,...",
    "url": "https://finance.yahoo.com/news/merck-deepens-oncology-vaccine-bets-031828719.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "01ae13a9-a70e-3609-9a7c-b5e0b02a120d",
      "content": {
        "id": "01ae13a9-a70e-3609-9a7c-b5e0b02a120d",
        "contentType": "STORY",
        "title": "Merck Deepens Oncology And Vaccine Bets With Partnerships And Equity Stake",
        "description": "",
        "summary": "Merck (NYSE:MRK) has taken a significant equity stake in Eikon Therapeutics, expanding its presence in oncology-focused biotech. The company has entered a global oncology collaboration with Guardant Health to advance cancer diagnostics and treatment approaches. Merck is also leading efforts to improve global access to vaccines targeting Zaire ebolavirus, aiming to broaden distribution and use. For you as an investor, these moves sit squarely within Merck's core areas in cancer and vaccines,...",
        "pubDate": "2026-02-04T03:18:28Z",
        "displayTime": "2026-02-04T03:18:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-deepens-oncology-vaccine-bets-031828719.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-deepens-oncology-vaccine-bets-031828719.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T06:08:04+00:00",
    "headline": "Merck & Co., Inc. Q4 Earnings Call Highlights",
    "summary": "Merck & Co., Inc. (NYSE:MRK) reported fourth-quarter 2025 revenue of $16.4 billion, up 5% year over year (4% excluding foreign exchange), as continued growth in oncology and animal health helped offset a sharp decline in Gardasil sales driven by weaker demand in China and Japan. Management also",
    "url": "https://www.marketbeat.com/instant-alerts/merck-co-inc-q4-earnings-call-highlights-2026-02-04/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "339052be-59d3-3370-8c6a-b77ed4d3df42",
      "content": {
        "id": "339052be-59d3-3370-8c6a-b77ed4d3df42",
        "contentType": "STORY",
        "title": "Merck & Co., Inc. Q4 Earnings Call Highlights",
        "description": "",
        "summary": "Merck & Co., Inc. (NYSE:MRK) reported fourth-quarter 2025 revenue of $16.4 billion, up 5% year over year (4% excluding foreign exchange), as continued growth in oncology and animal health helped offset a sharp decline in Gardasil sales driven by weaker demand in China and Japan. Management also",
        "pubDate": "2026-02-04T06:08:04Z",
        "displayTime": "2026-02-04T06:08:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/e23c38395a2f6cd099d4d7f775327c97",
          "originalWidth": 1200,
          "originalHeight": 1200,
          "caption": "Merck & Co., Inc. logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RoLR8pS2jP_VNEZ6RQ6nYg--~B/aD0xMjAwO3c9MTIwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/marketbeat_955/e23c38395a2f6cd099d4d7f775327c97.cf.webp",
              "width": 1200,
              "height": 1200,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PP8McusDEbIaqCDbJ_Ua2A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/e23c38395a2f6cd099d4d7f775327c97.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/merck-co-inc-q4-earnings-call-highlights-2026-02-04/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-inc-q4-earnings-060804398.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T09:00:00+00:00",
    "headline": "Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit",
    "summary": "Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage clinical setbacks in the field.Expanded Opportunity: Discussions with major pharmaceutical partners highlight emerging demand for novel antibody-drug conjugate (ADC) payloads, validating the potential of Rakovina’s kt-3000 series. VANCOUVER, British Columbia, Feb. 04, 2026 (GLOBE NEWSWIRE) -- R",
    "url": "https://finance.yahoo.com/news/rakovina-therapeutics-reports-strong-industry-090000759.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "cab83287-582e-3a52-81a2-c3251caab842",
      "content": {
        "id": "cab83287-582e-3a52-81a2-c3251caab842",
        "contentType": "STORY",
        "title": "Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit",
        "description": "",
        "summary": "Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage clinical setbacks in the field.Expanded Opportunity: Discussions with major pharmaceutical partners highlight emerging demand for novel antibody-drug conjugate (ADC) payloads, validating the potential of Rakovina’s kt-3000 series. VANCOUVER, British Columbia, Feb. 04, 2026 (GLOBE NEWSWIRE) -- R",
        "pubDate": "2026-02-04T09:00:00Z",
        "displayTime": "2026-02-04T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d77fbb0e233d7442f3dacfda4b8ce1eb",
          "originalWidth": 411,
          "originalHeight": 139,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jLdh5omwHviW9fKrxyTrOw--~B/aD0xMzk7dz00MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d77fbb0e233d7442f3dacfda4b8ce1eb.cf.webp",
              "width": 411,
              "height": 139,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cKNIqVQJ9S2NvViUnwQTJg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d77fbb0e233d7442f3dacfda4b8ce1eb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rakovina-therapeutics-reports-strong-industry-090000759.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rakovina-therapeutics-reports-strong-industry-090000759.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RKVTF"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T05:35:14+00:00",
    "headline": "MRK Q4 Deep Dive: Pipeline Expansion and New Product Launches Shape Guidance",
    "summary": "Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue guidance of $66.25 billion at the midpoint came in 2% below analysts’ estimates. Its non-GAAP profit of $2.04 per share was 1.5% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/mrk-q4-deep-dive-pipeline-053514301.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "b25150f7-f74c-3ee9-9f55-4354351d2654",
      "content": {
        "id": "b25150f7-f74c-3ee9-9f55-4354351d2654",
        "contentType": "STORY",
        "title": "MRK Q4 Deep Dive: Pipeline Expansion and New Product Launches Shape Guidance",
        "description": "",
        "summary": "Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue guidance of $66.25 billion at the midpoint came in 2% below analysts’ estimates. Its non-GAAP profit of $2.04 per share was 1.5% above analysts’ consensus estimates.",
        "pubDate": "2026-02-04T05:35:14Z",
        "displayTime": "2026-02-04T05:35:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/ebe2be3c9f70cfc1092fc0a56a0c75dc",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "MRK Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PqkkAVnP2lidjvyb58UUUQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/ebe2be3c9f70cfc1092fc0a56a0c75dc.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jUpD9l9St2LHULbO70D5fw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/ebe2be3c9f70cfc1092fc0a56a0c75dc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mrk-q4-deep-dive-pipeline-053514301.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mrk-q4-deep-dive-pipeline-053514301.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T15:16:06+00:00",
    "headline": "Stock Market Today: Dow Rises But Nasdaq Lags On Surprise Jobs Data; Eli Lilly Soars (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rose Wednesday after surprise jobs data. AMD stock plunged on earnings.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-amd-stock-amd-earnings/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "95eff06b-9fa2-3b22-b1b7-24055bf9706b",
      "content": {
        "id": "95eff06b-9fa2-3b22-b1b7-24055bf9706b",
        "contentType": "STORY",
        "title": "Stock Market Today: Dow Rises But Nasdaq Lags On Surprise Jobs Data; Eli Lilly Soars (Live Coverage)",
        "description": "",
        "summary": "Stock Market Today: The Dow Jones index rose Wednesday after surprise jobs data. AMD stock plunged on earnings.",
        "pubDate": "2026-02-04T15:16:06Z",
        "displayTime": "2026-02-04T15:16:06Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/95eff06b-9fa2-3b22-b1b7-24055bf9706b/stock-market-today-dow-rises.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/c17b5b65818a93054b26ab66c9c27269",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VXfiuJebQrJ7SF321xzdvQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/c17b5b65818a93054b26ab66c9c27269.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8VRw_x7TNp5peYlHXpe4og--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/c17b5b65818a93054b26ab66c9c27269.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-amd-stock-amd-earnings/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "IBM"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CRM"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T09:51:00+00:00",
    "headline": "Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan",
    "summary": "Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.",
    "url": "https://www.biopharmadive.com/news/amgen-pfizer-merck-fda-biotech-earnings-q4-2025/811287/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "07334471-b8eb-34c9-8fd9-d0a7d1034f79",
      "content": {
        "id": "07334471-b8eb-34c9-8fd9-d0a7d1034f79",
        "contentType": "STORY",
        "title": "Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan",
        "description": "",
        "summary": "Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.",
        "pubDate": "2026-02-04T09:51:00Z",
        "displayTime": "2026-02-04T09:51:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/d2f9ee485f2d1d56defe2e03f0780ca3",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "People walk by the New York Stock Exchange on February 14, 2023 in New York City.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TUUMCSP7jWZJ_xKWTP11ng--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/d2f9ee485f2d1d56defe2e03f0780ca3.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Mq64gO4UmFCGd0.vo1yfGQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/d2f9ee485f2d1d56defe2e03f0780ca3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/amgen-pfizer-merck-fda-biotech-earnings-q4-2025/811287/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/earnings-roundup-amgen-vs-fda-095100978.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T15:59:23+00:00",
    "headline": "Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says",
    "summary": "Merck's (MRK) internal pipeline progress and business development strategy take precedence over Q4 a",
    "url": "https://finance.yahoo.com/news/merck-apos-pipeline-progress-business-155923708.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "f5a8e2d6-243a-381e-8abb-e381ec4194f6",
      "content": {
        "id": "f5a8e2d6-243a-381e-8abb-e381ec4194f6",
        "contentType": "STORY",
        "title": "Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says",
        "description": "",
        "summary": "Merck's (MRK) internal pipeline progress and business development strategy take precedence over Q4 a",
        "pubDate": "2026-02-04T15:59:23Z",
        "displayTime": "2026-02-04T15:59:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-apos-pipeline-progress-business-155923708.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-apos-pipeline-progress-business-155923708.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MS"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T15:45:00+00:00",
    "headline": "Biopharmaceutical Industry Set for Unprecedented Growth in 2025: Key Trends and Contributions by Global Leaders",
    "summary": "According to Precedence Research, the global biopharmaceutical industry continues to experience robust growth in 2025, with the top 20 companies leading the charge in various therapeutic areas such as oncology, immunology, and vaccines. These industry giants are not only shaping healthcare innovations but also experiencing remarkable revenue growth. The list includes key players such as Merck & Co., Pfizer, and Johnson & Johnson, with each company contributing to the evolution of the biopharma l",
    "url": "https://finance.yahoo.com/news/biopharmaceutical-industry-set-unprecedented-growth-154500153.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "943eade1-2ab9-3255-bdc6-15097c59e631",
      "content": {
        "id": "943eade1-2ab9-3255-bdc6-15097c59e631",
        "contentType": "STORY",
        "title": "Biopharmaceutical Industry Set for Unprecedented Growth in 2025: Key Trends and Contributions by Global Leaders",
        "description": "",
        "summary": "According to Precedence Research, the global biopharmaceutical industry continues to experience robust growth in 2025, with the top 20 companies leading the charge in various therapeutic areas such as oncology, immunology, and vaccines. These industry giants are not only shaping healthcare innovations but also experiencing remarkable revenue growth. The list includes key players such as Merck & Co., Pfizer, and Johnson & Johnson, with each company contributing to the evolution of the biopharma l",
        "pubDate": "2026-02-04T15:45:00Z",
        "displayTime": "2026-02-04T15:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/47160fa420d06f24420d9a27698245a7",
          "originalWidth": 1667,
          "originalHeight": 1667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2XVm_GDF06LCL8xJEgs9kg--~B/aD0xNjY3O3c9MTY2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/47160fa420d06f24420d9a27698245a7.cf.webp",
              "width": 1667,
              "height": 1667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ciHBcKYhN1HkkZYm0oIo1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/47160fa420d06f24420d9a27698245a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biopharmaceutical-industry-set-unprecedented-growth-154500153.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biopharmaceutical-industry-set-unprecedented-growth-154500153.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T17:16:27+00:00",
    "headline": "Assessing Merck (MRK) Valuation After 2025 Earnings Beat And Softer 2026 Outlook",
    "summary": "Merck (MRK) just reported its fourth quarter and full year 2025 results, pairing higher sales with softer quarterly profit and a 2026 sales outlook of US$65.5b to US$67.0b that trailed market expectations. See our latest analysis for Merck. Despite the softer 2026 outlook, Merck’s share price has been on a strong run, with a 90 day share price return of 37.27% and a 1 year total shareholder return of 32.46%. This suggests momentum has been building around its earnings delivery, acquisitions...",
    "url": "https://finance.yahoo.com/news/assessing-merck-mrk-valuation-2025-171627607.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b804e58e-cb7d-3f42-ad18-67e295093b2e",
      "content": {
        "id": "b804e58e-cb7d-3f42-ad18-67e295093b2e",
        "contentType": "STORY",
        "title": "Assessing Merck (MRK) Valuation After 2025 Earnings Beat And Softer 2026 Outlook",
        "description": "",
        "summary": "Merck (MRK) just reported its fourth quarter and full year 2025 results, pairing higher sales with softer quarterly profit and a 2026 sales outlook of US$65.5b to US$67.0b that trailed market expectations. See our latest analysis for Merck. Despite the softer 2026 outlook, Merck’s share price has been on a strong run, with a 90 day share price return of 37.27% and a 1 year total shareholder return of 32.46%. This suggests momentum has been building around its earnings delivery, acquisitions...",
        "pubDate": "2026-02-04T17:16:27Z",
        "displayTime": "2026-02-04T17:16:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-merck-mrk-valuation-2025-171627607.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-merck-mrk-valuation-2025-171627607.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T20:18:36+00:00",
    "headline": "Jim Cramer on Merck & Co.: “This Is One of My Favorite Pharmaceutical Stocks”",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer looked at recently. Cramer discussed the company’s latest quarter, as he commented: This morning, Merck reported a very solid quarter, but gave what some people thought was a soft full-year forecast, yet the stock finished up the session more than 2%. Why? Because […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-merck-co-one-201836887.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ad3387de-448c-30f9-831b-69d467a9063e",
      "content": {
        "id": "ad3387de-448c-30f9-831b-69d467a9063e",
        "contentType": "STORY",
        "title": "Jim Cramer on Merck & Co.: “This Is One of My Favorite Pharmaceutical Stocks”",
        "description": "",
        "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer looked at recently. Cramer discussed the company’s latest quarter, as he commented: This morning, Merck reported a very solid quarter, but gave what some people thought was a soft full-year forecast, yet the stock finished up the session more than 2%. Why? Because […]",
        "pubDate": "2026-02-04T20:18:36Z",
        "displayTime": "2026-02-04T20:18:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/ab17cbae959ed841325f2d9cbe730e2f",
          "originalWidth": 1920,
          "originalHeight": 2880,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QXEKpOetBRhUDcNGKlL0cg--~B/aD0yODgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/ab17cbae959ed841325f2d9cbe730e2f.cf.webp",
              "width": 1920,
              "height": 2880,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VDRmPqyu1EoBbyHk7S0x7A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ab17cbae959ed841325f2d9cbe730e2f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-merck-co-one-201836887.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-merck-co-one-201836887.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]